<DOC>
	<DOC>NCT00412529</DOC>
	<brief_summary>This exploratory study is designed to determine the early viral kinetic profile during treatment with telbivudine or entecavir at multiple time points over 12 weeks.</brief_summary>
	<brief_title>Viral Kinetics Study of Telbivudine and Entecavir in Adults With Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Male or female, 1870 years of age with documented compensated hepatitis B "e" antigen (HBeAg)positive chronic hepatitis B Able to comply with study regimen and provide written informed consent Pregnant or breastfeeding Unwilling to use double barrier method of contraception Coinfected with hepatitis C virus (HCV), hepatitis D virus (HDV) or human immunodeficiency virus (HIV) Received Hepatitis B therapy in the past Use of immunomodulatory therapy in past 12 months History of or symptoms of hepatic decompensation or pancreatitis Frequent or prolonged use of potentially hepatotoxic or nephrotoxic drugs Concurrent medication likely to preclude compliance with schedule of evaluations Use of other investigational drugs within 30 days of enrollment Abnormal laboratory values during screening Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>HBeAg-positive, chronic hepatitis B</keyword>
	<keyword>telbivudine</keyword>
	<keyword>entecavir</keyword>
	<keyword>viral kinetics</keyword>
</DOC>